Inclusion Criteria:

- Diagnosis of MDS by bone marrow biopsy based on the World Health
Organization (WHO) classification - Low, Intermediate-1 or Intermediate-2 risk category
MDS using the IPSS (International Prognostic Scoring System) - Planned to receive either
azacytidine 75 mg/m2 by subcutaneous administration each day for 7 days or decitabine 20
mg/m2 by intravenous administration each day for 5 days for at least 4 cycles Exclusion
Criteria:

- Prior exposure to >3 cycles hypomethylating agents

- Prior history of leukemia or aplastic anemia

- Prior history of bone marrow transplantation

- Prior malignancy (other than in situ cervical cancer or basal cell cancer of the
skin) unless treated with curative intent and without evidence of disease for ³ 3
years before randomization

- Active or uncontrolled infections

- Unstable angina, congestive heart failure [NYHA (New York Heart Association) > class
II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac
arrhythmia, or recent (within 1 year) myocardial infarction

- History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past
year

- History of venous thrombosis that currently requires anti-coagulation therapy

- Received IL-11 within 4 weeks of screening

- Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA
approved for any indication

- Have previously received any other thrombopoietic growth factor